My PCR
Create Account
Logo PCR

Stable CAD (Coronary artery disease)

Latest stable coronary artery disease (stable CAD) content in interventional cardiology - research, practice, and education

A complex and changing disease state requiring wide expertise, stable CAD can involve a diverse range of underlying chronic or evolutionary stages involving full use of all available tools, devices and techniques like those for invasive imaging and functional assessment. Taking into account underlying comorbidities such as diabetes is critical. Advances in imaging techniques, as well as the use of adjunctive pharmacotherapy, vascular access or invasive interventions such as bypass surgery, are important, as are understanding bleeding risks, all of which can be found here…

Filtered By
Stable CAD

305 results

Refactory angina and coronary sinus reducer, from established applications to future outlooks

21 May 2026 – From EuroPCR 2026

In this discussion, Tim van de Hoef and Tommaso Gori explore the evolving definition of refractory angina, extending beyond obstructive disease to include non-obstructive and microvascular conditions. They highlight the challenges of recognition, driven by variability in symptoms, diagnostic approaches, and clinical practices, and stress that...

Refactory angina and coronary sinus reducer, from established applications to future outlooks

Spontaneous coronary artery dissection management with intracoronary imaging

22 May 2026 – From EuroPCR 2026

Explore the nuanced management of spontaneous coronary artery dissection (SCAD) with a focus on intracoronary imaging. This session examines diagnostic challenges, the limited role of coronary CT angiography, and strategies for managing occlusive SCAD cases, highlighting the evolving understanding of this complex condition.

ARTICA: Coronary revascularisation in patients undergoing TAVI - an individual patient data meta-analysis of 4 randomised trials

21 May 2026 – From EuroPCR 2026

At EuroPCR 2026, Martin Leon and Roberto Scarsini review ARTICA, a patient-level meta-analysis combining data from the ACTIVATION, NOTION-3, FAITAVI, and TCW randomised trials.

The analysis included 1,050 patients with severe aortic stenosis and concomitant coronary artery disease and compared three management strategies: medical therapy, angiography-guided PCI,...

Coronary revascularisation in patients undergoing TAVI, an indivual patient data meta-analysis of 4 randomised trials

New evidence for coronary revascularisation

21 May 2026 – From EuroPCR 2026

This session highlights new evidence in coronary revascularisation, including the role of CT-derived virtual stenting for procedural optimization, left ventricular unloading during complex PCI, long-term outcomes of FFR-guided PCI versus medical therapy, Impella CP support in high-risk PCI, and comparative results of PCI versus CABG in...

Asymptomatic high-risk patients: can CT coronary angiography improve our practice?

21 May 2026 – From EuroPCR 2026

This session examines the role of cardiac computed tomography (CT) coronary angiography in improving clinical practice for asymptomatic high-risk patients. It discusses detection of vulnerable plaque features, the importance of inflammation and physiology in risk assessment, and explores individualized treatment pathways including PCI, medical therapy, or...

Refining PCI plannings and decision-making with novel technologies

21 May 2026 – From EuroPCR 2026

This session highlights cutting-edge technologies that enhance PCI planning and decision-making. It covers the clinical populations benefiting from QFR-guided revascularisation, prognostic insights from radial wall strain in DCB-treated vessels, and advances in artificial intelligence and machine learning to assess ischemia and predict PCI outcomes, especially in...

New evidence in coronary physiology for microvascular assessment

21 May 2026 – From EuroPCR 2026

This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.

INOCA in patients with coronary artery disease

21 May 2026 – From EuroPCR 2026

This session focuses on ischaemia with non-obstructive coronary arteries (INOCA) in patients with coronary artery disease. It raises awareness of common clinical presentations, emphasizes accurate diagnosis through functional coronary testing, and discusses how tailored treatment strategies can improve patient outcomes in this frequently under-recognized condition.

Diagnosis and management of INOCA and ANOCA

21 May 2026 – From EuroPCR 2026

This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...

Incorporating CT coronary angiography in the cathlab practice

21 May 2026 – From EuroPCR 2026

Explore the integration of CT coronary angiography into catheterization laboratory practice through real-world studies assessing anatomical yield, diagnostic accuracy, and physiological assessments. The session highlights advancements in myocardial blood flow analysis and plaque characterization to improve ischemia detection and guide invasive angiography.